99 related articles for article (PubMed ID: 20664901)
1. TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet-leukocyte interaction in human whole blood.
Miyamoto M; Ohno M; Yamada N; Ohtake A; Matsushita T
Thromb Haemost; 2010 Oct; 104(4):788-95. PubMed ID: 20664901
[TBL] [Abstract][Full Text] [Related]
2. TRA-418, a novel compound having both thromboxane A(2) receptor antagonistic and prostaglandin I(2) receptor agonistic activities: its antiplatelet effects in human and animal platelets.
Yamada N; Miyamoto M; Isogaya M; Suzuki M; Ikezawa S; Ohno M; Otake A; Umemura K
J Thromb Haemost; 2003 Aug; 1(8):1813-9. PubMed ID: 12911598
[TBL] [Abstract][Full Text] [Related]
3. Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation.
Miyamoto M; Yamada N; Ikezawa S; Ohno M; Otake A; Umemura K; Matsushita T
Br J Pharmacol; 2003 Nov; 140(5):889-94. PubMed ID: 14504133
[TBL] [Abstract][Full Text] [Related]
4. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets.
Jin YR; Cho MR; Lee KS; Lee JJ; Lim Y; Han XH; Oh KW; Hong JT; Yoo HS; Yun YP
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):162-7. PubMed ID: 16128910
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of beraprost on platelet aggregation: comparative study utilizing two methods of aggregometry.
Yang L; Yatomi Y; Satoh K; Ozaki Y
Thromb Res; 1999 Apr; 94(1):25-32. PubMed ID: 10213178
[TBL] [Abstract][Full Text] [Related]
6. A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models.
Huang SW; Kuo HL; Hsu MT; Tseng YJ; Lin SW; Kuo SC; Peng HC; Lien JC; Huang TF
Thromb Haemost; 2016 Aug; 116(2):285-99. PubMed ID: 27173725
[TBL] [Abstract][Full Text] [Related]
7. Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle.
Yoshida M; Sato Y; Shimura T; Ohkubo S; Honma S; Tanaka T; Kurimoto T; Nakahata N
Pharmacology; 2007; 79(1):50-6. PubMed ID: 17139194
[TBL] [Abstract][Full Text] [Related]
8. The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization.
Walsh MT; Foley JF; Kinsella BT
J Biol Chem; 2000 Jul; 275(27):20412-23. PubMed ID: 10827090
[TBL] [Abstract][Full Text] [Related]
9. Thrombin receptor activating peptide (SFLLRN) potentiates shear-induced platelet microvesiculation.
Chow TW; Hellums JD; Thiagarajan P
J Lab Clin Med; 2000 Jan; 135(1):66-72. PubMed ID: 10638696
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol attenuates thromboxane A2 receptor agonist-induced platelet activation by reducing phospholipase C activity.
Yang YM; Chen JZ; Wang XX; Wang SJ; Hu H; Wang HQ
Eur J Pharmacol; 2008 Mar; 583(1):148-55. PubMed ID: 18291361
[TBL] [Abstract][Full Text] [Related]
11. Piperlongumine, a constituent of Piper longum L., inhibits rabbit platelet aggregation as a thromboxane A(2) receptor antagonist.
Iwashita M; Oka N; Ohkubo S; Saito M; Nakahata N
Eur J Pharmacol; 2007 Sep; 570(1-3):38-42. PubMed ID: 17618620
[TBL] [Abstract][Full Text] [Related]
12. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
13. Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells: role of receptor heterodimerization.
Wilson SJ; Dowling JK; Zhao L; Carnish E; Smyth EM
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):290-6. PubMed ID: 17110599
[TBL] [Abstract][Full Text] [Related]
14. Desensitisation of human platelets against stimulation by thromboxane mimics--reduction in receptor capacity and loss of functional response.
Thierauch KH; Gabriel D; Prior G; Schillinger E
Biomed Biochim Acta; 1988; 47(10-11):S75-8. PubMed ID: 2470362
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of adrenaline vasoconstrictor response by sub-threshold concentrations of U-46619 in human umbilical vein: involvement of smooth muscle prostanoid TP(alpha) receptor isoform.
Errasti AE; Luciani LI; Cesio CE; Tramontano J; Boveris D; Daray FM; Nowak W; Pelorosso FG; Rothlin RP
Eur J Pharmacol; 2007 May; 562(3):227-35. PubMed ID: 17362923
[TBL] [Abstract][Full Text] [Related]
17. Role of prostacyclin in the cardiovascular response to thromboxane A2.
Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA
Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481
[TBL] [Abstract][Full Text] [Related]
18. Epinephrine correction of impaired platelet thromboxane receptor signaling.
Dunlop PC; Leis LA; Johnson GJ
Am J Physiol Cell Physiol; 2000 Dec; 279(6):C1760-71. PubMed ID: 11078690
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation.
Meja KK; Barnes PJ; Giembycz MA
Br J Pharmacol; 1997 Sep; 122(1):149-57. PubMed ID: 9298541
[TBL] [Abstract][Full Text] [Related]
20. Direct myocardial effects of the thromboxane A2/prostaglandin H2 agonists U-46619 and SQ 26,655 under ischemic and nonischemic conditions.
Grover GJ; Hedberg A; Ogletree ML
Pharmacology; 1990; 41(1):1-15. PubMed ID: 2122481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
